Orion Pharma Animal Health
Pharmaceutical ManufacturingView the employees at
Orion Pharma Animal Health-
Anna-Karin Winberg B2B and customer relationship professional - getting things done! I am a sales professional with >10 years experience from international B2B sales, and speaking four languages.
-
Espoo, Uusimaa, Finland
-
Top 5%
Mette Skovdal Lægemiddelkonsulent - Orion-
Silkeborg, Middle Jutland, Denmark
-
Rising Star
Paulina Szczepańska Sales Representative w Orion Pharma Animal Health-
Wrocław, Dolnośląskie, Poland
-
Rising Star
Victor von Segebaden Product Manager/ Product Specialst- Orion Pharma Animal Health-
Lund, Kalmar County, Sweden
-
Rising Star
MVDr. Tereza Pecinová Doktor veterinární medicíny-
Brno, South Moravia, Czechia
-
Rising Star
Overview
Orion Pharma Animal Health is part of Orion Group, a Finnish pharmaceutical company that operates worldwide to bring well-being to both people and animals. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. At Orion Pharma Animal Health, we work to improve the health and well-being of animals everywhere. We offer modern veterinary solutions including medicines, non-medicinal products, expertise, and services. Our core team consists of over 70 people working in sales and marketing. Research and development and other supportive functions are provided by the Orion Corporation, including 50 veterinarians who have all dedicated their life’s work to animals and their well-being. Our products and services are sold worldwide by our own sales teams as well as our partners. Orion Pharma Animal Health sales organisations are located in Finland, Sweden, Norway, Denmark, Poland, Hungary, Romania, Czech Republic, Slovakia, Belgium, France, Estonia, Lithuania, Latvia and Vietnam. Our headquarters is located in Espoo, Finland. Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods from which patients get help for their illnesses. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees globally at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
-